DE122005000005I1 - Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz. - Google Patents

Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz.

Info

Publication number
DE122005000005I1
DE122005000005I1 DE1994627337 DE69427337C DE122005000005I1 DE 122005000005 I1 DE122005000005 I1 DE 122005000005I1 DE 1994627337 DE1994627337 DE 1994627337 DE 69427337 C DE69427337 C DE 69427337C DE 122005000005 I1 DE122005000005 I1 DE 122005000005I1
Authority
DE
Germany
Prior art keywords
venlafaxine
aryloxy
incontinence
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE1994627337
Other languages
English (en)
Other versions
DE122005000005I2 (de
DE69427337T2 (de
DE69427337D1 (de
Inventor
Karl Bruce Thor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22566762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122005000005(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of DE122005000005I1 publication Critical patent/DE122005000005I1/de
Publication of DE122005000005I2 publication Critical patent/DE122005000005I2/de
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE1994627337 1993-11-24 1994-11-22 Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz Active DE122005000005I2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15812193A 1993-11-24 1993-11-24

Publications (2)

Publication Number Publication Date
DE122005000005I1 true DE122005000005I1 (de) 2005-05-12
DE122005000005I2 DE122005000005I2 (de) 2006-06-08

Family

ID=22566762

Family Applications (2)

Application Number Title Priority Date Filing Date
DE1994627337 Active DE122005000005I2 (de) 1993-11-24 1994-11-22 Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz
DE69427337T Expired - Lifetime DE69427337T2 (de) 1993-11-24 1994-11-22 Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69427337T Expired - Lifetime DE69427337T2 (de) 1993-11-24 1994-11-22 Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz

Country Status (28)

Country Link
US (1) US5744474A (de)
EP (1) EP0654264B1 (de)
JP (1) JP3681009B2 (de)
KR (1) KR100347277B1 (de)
CN (1) CN1099284C (de)
AT (1) ATE201594T1 (de)
AU (1) AU679269B2 (de)
CA (1) CA2136120C (de)
CY (2) CY2245B1 (de)
CZ (1) CZ289069B6 (de)
DE (2) DE122005000005I2 (de)
DK (1) DK0654264T3 (de)
ES (1) ES2157958T3 (de)
GE (1) GEP20064000B (de)
GR (1) GR3036446T3 (de)
HK (1) HK1013799A1 (de)
HU (1) HU218920B (de)
IL (1) IL111705A (de)
LU (1) LU91140I2 (de)
NL (1) NL300174I2 (de)
NO (2) NO313535B1 (de)
PH (1) PH30741A (de)
PT (1) PT654264E (de)
RU (1) RU2152786C2 (de)
SI (1) SI0654264T1 (de)
TW (1) TW344661B (de)
UA (1) UA32429C2 (de)
ZA (1) ZA949190B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506270A (en) * 1995-01-30 1996-04-09 American Home Products Corporation Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
RO117296B1 (ro) * 1996-03-11 2002-01-30 Lilly Co Eli Metoda pentru tratarea sau prevenirea cistitei interstitiale
EP1331003B1 (de) * 1996-03-25 2015-08-26 Wyeth LLC Venlafaxinhaltige Arzneizusammensetzung mit verzögerter Wirkstoffabgabe
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
US6150396A (en) * 1997-03-07 2000-11-21 Eli Lilly And Company Methods of treating or preventing interstitial cystitis
JP2002520353A (ja) * 1998-07-16 2002-07-09 マサチューセッツ インスティテュート オブ テクノロジー ストレスの処置のための組成物
US6579899B1 (en) 1998-07-16 2003-06-17 Massachusetts Institute Of Technology Composition for treatment of stress
EA002720B1 (ru) * 1998-08-27 2002-08-29 Фармациа Энд Апджон Аб Терапевтическая композиция для введения толтеродина с контролируемым высвобождением и способ лечения мочевого пузыря с её использованием
US6046242A (en) * 1998-11-27 2000-04-04 Basf Aktiengesellschaft Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
US6197828B1 (en) * 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
EP1905757A1 (de) * 1999-04-06 2008-04-02 Sepracor Inc. Derivate von Venlafaxin und Verfahren zu ihrer Herstellung und Verwendung
HUP0201623A3 (en) 1999-07-01 2004-12-28 Upjohn Co Use of (s,s)reboxetine a selective norepinephrine reuptake inhibitor for the preparation of pharmaceutical compositions treating disorders of the nervous system
US7291646B2 (en) 1999-11-24 2007-11-06 Wyeth Ethers of O-desmethyl venlafaxine
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
DE10027290C2 (de) 2000-06-02 2002-07-11 Basf Coatings Ag Pulverklarlackdispersionen (Pulverslurry-Klarlacke) und ihre Verwendung
DE10059412A1 (de) * 2000-11-30 2002-06-13 Gruenenthal Gmbh Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie der Harninkontinenz
PE20020877A1 (es) * 2001-02-12 2002-11-12 Wyeth Corp Succinato de o-desmetil-venlafaxina
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US7030164B2 (en) * 2001-12-05 2006-04-18 Wyeth Crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
UA77234C2 (en) * 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
GB0202265D0 (en) * 2002-01-31 2002-03-20 Arachnova Therapeutics Ltd New therapeutic use
AR039164A1 (es) * 2002-03-28 2005-02-09 Synthon Bv Sales de venlafaxina de baja solubilidad en agua
WO2003090743A1 (en) * 2002-04-24 2003-11-06 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders
DE10224107A1 (de) * 2002-05-29 2003-12-11 Gruenenthal Gmbh Kombination ausgewählter Opioide mit anderen Wirkstoffen zur Therapie der Harninkontinenz
AU2003268361A1 (en) * 2002-08-30 2004-03-19 Watson Pharmaceuticals, Inc. Drug delivery system for treating urinary incontinence
GB0221438D0 (en) * 2002-09-16 2002-10-23 Avecia Ltd Processes and compounds
EP1424079A1 (de) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Kombination eines beta-3-Rezeptoragonisten und eines Serotonin und/oder Norepinephrin-Wiederaufnahmeinhibitors
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
ATE365554T1 (de) * 2003-04-04 2007-07-15 Dynogen Pharmaceuticals Inc Methode zur behandlung von erkrankungen der unteren harnwege
WO2005105763A1 (en) * 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
EP2400300A1 (de) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Screeningverfahren von Mitteln zur Prävention/Behandlung von stressbedingter Harninkontinenz
JP2007523213A (ja) * 2004-12-23 2007-08-16 テバ ファーマシューティカル インダストリーズ リミティド 医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法
US7534900B2 (en) * 2005-03-14 2009-05-19 Teva Pharmaceutical Industries Ltd Process for the purification of duloxetine hydrochloride
US7842717B2 (en) 2005-09-22 2010-11-30 Teva Pharmaceutical Industries Ltd. DNT-maleate and methods of preparation thereof
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
ES2549079T3 (es) 2005-12-01 2015-10-22 Auspex Pharmaceuticals, Inc. Fenetilaminas sustituidas con actividad serotoninérgica y/o norepinefrinérgica
EP1863782A1 (de) 2005-12-05 2007-12-12 Teva Pharmaceutical Industries Ltd. 2-(n-methyl-propanamin)-3-(2-naphthol) thiophen, eine verunreinigung von duloxetin hydrochlorid
CA2629609A1 (en) 2005-12-05 2007-06-14 Wyeth Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols
EP1826204A1 (de) 2006-02-28 2007-08-29 Laboratorios Del Dr. Esteve, S.A. Verfahren zur Herstellung enantomerer Ausgangsverbindungen von Duloxetin
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
EP2125698B1 (de) 2007-03-15 2016-08-31 Auspex Pharmaceuticals, Inc. DEUTERIERTES d9-VENLAFAXINE
EP3820563A4 (de) 2018-07-11 2022-05-04 Dignify Therapeutics, LLC Verfahren zur behandlung von entleerungsdysfunktion

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
CA1181430A (en) * 1980-11-14 1985-01-22 Bennie J. Foster (-) - n-methyl-3-(2-methylphenox)-3-phenylpropylamine, antidepressant
IE56324B1 (en) * 1982-12-13 1991-06-19 American Home Prod Phenethylamine derivatives and intermediates therefor
US4761501A (en) * 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
KR880007433A (ko) * 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
PT87163B (pt) * 1987-04-09 1992-07-31 Lilly Co Eli Processo para a preparacao de 1-fenil-3-naftaleniloxi-propanaminas
SE8804003D0 (sv) * 1988-11-04 1988-11-04 Pharmacia Ab Compounds for the treatment of urinary incontinence
US5250571A (en) * 1988-11-14 1993-10-05 Eli Lilly And Company (S)-norfluoxetine in method of inhibiting serotonin uptake
AU642582B2 (en) * 1991-02-25 1993-10-21 Eli Lilly And Company Treatment of lower urinary tract disorders
EP0537915B1 (de) * 1991-09-27 1995-07-12 Eli Lilly And Company N-Alkyl-3-phenyl-3-(2-alkylthiophenoxy)Propylamine als Norepinephrineinhibitoren
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

Also Published As

Publication number Publication date
ATE201594T1 (de) 2001-06-15
NO313535B1 (no) 2002-10-21
HUT72317A (en) 1996-04-29
JP3681009B2 (ja) 2005-08-10
PT654264E (pt) 2001-09-28
CN1099284C (zh) 2003-01-22
ES2157958T3 (es) 2001-09-01
TW344661B (en) 1998-11-11
CZ289394A3 (en) 1995-07-12
CY2245B1 (en) 2003-07-04
UA32429C2 (uk) 2000-12-15
CA2136120A1 (en) 1995-05-25
GEP20064000B (en) 2006-12-11
DE122005000005I2 (de) 2006-06-08
SI0654264T1 (en) 2001-10-31
GR3036446T3 (en) 2001-11-30
CY2005002I1 (el) 2010-07-28
DE69427337T2 (de) 2001-10-31
LU91140I2 (fr) 2005-04-04
RU94041950A (ru) 1996-09-20
NL300174I1 (nl) 2005-04-01
JPH07188003A (ja) 1995-07-25
IL111705A (en) 2001-01-11
NO2005004I1 (no) 2005-02-10
KR950013511A (ko) 1995-06-15
HU9403369D0 (en) 1995-02-28
CZ289069B6 (cs) 2001-10-17
PH30741A (en) 1997-10-17
IL111705A0 (en) 1995-01-24
EP0654264B1 (de) 2001-05-30
AU679269B2 (en) 1997-06-26
CN1107699A (zh) 1995-09-06
ZA949190B (en) 1996-05-20
DK0654264T3 (da) 2001-07-30
NO944456D0 (no) 1994-11-21
NO944456L (no) 1995-05-26
CA2136120C (en) 2008-01-29
HU218920B (hu) 2000-12-28
DE69427337D1 (de) 2001-07-05
NL300174I2 (nl) 2005-05-02
KR100347277B1 (ko) 2003-03-06
CY2005002I2 (el) 2010-07-28
AU7896894A (en) 1995-06-01
US5744474A (en) 1998-04-28
HK1013799A1 (en) 1999-09-10
RU2152786C2 (ru) 2000-07-20
EP0654264A1 (de) 1995-05-24

Similar Documents

Publication Publication Date Title
DE122005000005I1 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz.
DE122005000002I1 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz.
DE69524679T2 (de) Verwendung Rapamycin zur Herstellung eines Medikaments für die Verbeugung und Behandlung von hyperproliferativen Gefässerkrankheiten, eventuell in Kombination mit Mycophenolsäure
DE69207847D1 (de) Verwendung von Rapamycin zur Herstellung eines Arzneimittels zur Behandlung von Augenentzündungen
DE69818058D1 (de) Verwendung von polyallylamin-polymeren zur herstellung eines medikamentes zur behandlung von hypercholesterolemia
DE69229944T2 (de) Verwendung von N-Acylaminoalkoholen zur Herstellung eines Arzneimittels zur Behandlung von Mastzellerkrankungen
DE69423577T2 (de) Verwendung von Oenothein B zur Herstellung eines Medikaments zur Behandlung der durch Hyperandrogenität bedingte Störungen.
DE69301750T2 (de) Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose
DE69716341D1 (de) Verwendung von Alkanoyl-L-Carnitinen zur Herstellung eines Arzneimittels zur Behandlung von entzündlichen Darmerkrankungen
DE69632677D1 (de) Verwendung eines Rifamycin-Derivates zur Herstellung eines Medikamentes zur Behandlung von Krankheiten verursacht durch Helicobacter pylori-Infektionen
DE68916777D1 (de) Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis.
ATE173921T1 (de) Verwendung von deoxyspergualin zur herstellung eines arzneimittels zur behandlung von entzündlich-hyperreaktiven erkrankungen
ATE107166T1 (de) Verwendung von chlormethiazol zur herstellung eines artzneimittels zur prophylaxe oder therapie der neurodegeneration.
DE3585312D1 (de) Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyrido(1,2-a)pyrimidin-3-carboxamid zur vorbeugung und behandlung von gastrointestinalschaeden.
DE69215191T2 (de) Verwendung von thiol-5-(2-diethyl-aminoethyl)-ester-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung der neuromuskuläre Inkontinenz
DE69529070D1 (de) Verwendung von 5,6-o-benzyliden-l-ascorbinsäure oder deren salze zur herstellung eines medikaments zur behandlung von hiv
DE60117189D1 (de) Verfahren zur Behandlung von medizinisch-chirurgischen Prothesen aus synthetischen Harzen für Menschen oder Tiere